Australia's Syntara rises on FDA's Fast Track approval for cancer drug

Syntara

10/06/2025 02:37

** Syntara shares SNT.AX rise 5.8% to A$0.073, their highest level since May 21

** Drug development firm says US FDA grants Fast Track designation to its myelofibrosis drug SNT5505

** The approval allows expedition of the review and development of therapies that address serious conditions and unmet medical needs, facilitating earlier drug approval and patient access

** Myelofibrosis is a type of blood cancer. Drug targets patients with insufficient response to Janus kinase inhibitor therapy

** Stock down 10% YTD

 (Reporting by Sneha Kumar in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))